SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1434Long-Term Study Shows Indiplon Capsules Effective at Promoting Sleep Onset and Mmopgcw-5/25/2005
1433far out dude10K a day-5/24/2005
1432NEW ROCHELLE, N.Y.--(Business Wire)--May 24, 2005-- Medicinal chemistry is playLJM-5/24/2005
1431How can one trust the research when they don't even know how to do a PDUFA dRobohogs-5/2/2005
1430SSB: NBIX: Indiplon Remains the Focus; Revising Target Price mopgcw-5/2/2005
1429Has anybody looked at other oral GNRH agonists in development, esp. progenta?keokalani'nui-4/29/2005
1428Neurocrine Biosciences Reports First Quarter 2005 Results Thursday April 28, 4:0mopgcw-4/28/2005
1427May I take a stab at this? >>If Lunesta does poorly, it may taint the wLJM-4/28/2005
1426May I take a stab at this? >>If Lunesta does poorly, it may taint the wLJM-4/28/2005
1425Thanks for the note. Do you think Ambien's tolerance issue will sabotage CRRobohogs-4/28/2005
1424Almost. Modestly superior? At least I think there is enough of a difference thakeokalani'nui-4/27/2005
1423Spot on. No doubt about it, overall market sentiment looks grim via charting. LJM-4/27/2005
1422<i>I just find charts don't work that well in biotech which is so eventom pope-4/27/2005
1421You are so right about that chart. I mainly use point and figure and it points LJM-4/27/2005
1420I noticed a bit in the tone of Wilder that he thinks Indi is actually much betteRobohogs-4/27/2005
1419I agree with your equivalence, marketing wise between Lunesta and Indiplon, and tom pope-4/27/2005
1418You are absolutely right of course. People like me do not <at this point>LJM-4/27/2005
1417My answer not to the question? From your post at Message 21270157 I swear you keokalani'nui-4/27/2005
1416>>IMO, after the detailed marketing push, Lunesta will compete head-on witLJM-4/27/2005
1415Difficult to say why the share price has lost so much. I was always surprised thIcebrg-4/27/2005
1414You guys can get a lot of info just by trying a little harder! For example, youkeokalani'nui-4/27/2005
1413One thing you might want to keep in mind. I keep hearing about the big advantagebiotek-al-4/27/2005
1412Thanks for your info. IYO, was this decline of about 50 percent for the year beLJM-4/27/2005
1411The general idea appears to be that helped by the marketing weight of Pfizer, InIcebrg-4/27/2005
1410I see NBIX hit a fresh 52-wk low today. I have had this company on my watchlistLJM-4/27/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News